Immunomedics IncFind Ratings Reports
IMMUNOMEDICS INC's gross profit margin for the second quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. IMMUNOMEDICS INC has strong liquidity. Currently, the Quick Ratio is 1.62 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 138.35% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY17||Q2 FY16|
|Net Sales ($mil)||0.38||0.67|
|Net Income ($mil)||-24.45||-13.75|
|Balance Sheet||Q2 FY17||Q2 FY16|
|Cash & Equiv. ($mil)||46.61||76.04|
|Total Assets ($mil)||53.12||81.96|
|Total Debt ($mil)||97.72||96.99|
|Profitability||Q2 FY17||Q2 FY16|
|Gross Profit Margin||-3939.32||-2314.46|
|Return on Assets||-132.78||-65.02|
|Return on Equity||0.0||0.0|
|Debt||Q2 FY17||Q2 FY16|
|Share Data||Q2 FY17||Q2 FY16|
|Shares outstanding (mil)||105.99||94.71|
|Div / share||0.0||0.0|
|Book value / share||-0.7||-0.33|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2939585.0||1714938.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium.
|IMMU NM||Peers 37.42||IMMU NM||Peers 19.90|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
IMMU's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
IMMU's P/CF is negative making the measure meaningless.
|IMMU 341.33||Peers 41.46||IMMU NA||Peers 0.53|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
IMMU's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|IMMU NM||Peers 11.06||IMMU -26.31||Peers 125.26|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
IMMU's P/B is negative making this valuation measure meaningless.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, IMMU is expected to significantly trail its peers on the basis of its earnings growth rate.
|IMMU 183.34||Peers 146.34||IMMU -40.63||Peers 626.06|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
IMMU is trading at a significant premium to its industry.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
IMMU significantly trails its peers on the basis of sales growth